These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3700041)

  • 1. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
    Arseneau JC; Schoenfeld DA; Borden EC
    Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
    Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
    Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone in malignant melanoma.
    Presant CA; Gams R; Bartolucci A
    Cancer Treat Rep; 1984 Jun; 68(6):903-5. PubMed ID: 6733704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
    Valdivieso M; Umsawasdi T; Spitzer G; Chiuten DF; Booser DJ; Dhingra HM; Bodey GP
    Am J Clin Oncol; 1984 Jun; 7(3):241-4. PubMed ID: 6328968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of mitoxantrone on a daily X 5 schedule.
    Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
    Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
    Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE
    Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
    DeSimone PA; Gams R; Bartolucci A
    Am J Clin Oncol; 1984 Oct; 7(5):517-22. PubMed ID: 6507372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
    Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
    Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
    Coleman RE; Maisey MN; Knight RK; Rubens RD
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone in malignant lymphoma.
    Gams RA; Bryan S; Dukart G; Weiss A; Case D; Jones S; Stein R
    Invest New Drugs; 1985; 3(2):219-22. PubMed ID: 4019123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of mitoxantrone in advanced breast cancer].
    Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
    Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
    Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
    Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study.
    Mouridsen HT; Rose C; Nooy MA; van Oosterom AT
    Cancer Treat Rev; 1983 Dec; 10 Suppl B():47-52. PubMed ID: 6661734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    Coates AS; Bishop J; Mann GJ; Raghavan D
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
    Stuart-Harris RC; Smith IE
    Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase II study of mitoxantrone in malignant lymphoma].
    Ibuka T; Sasaki T; Imai K; Sakai Y
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2612-7. PubMed ID: 3740861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.